CD274 and non-small cell lung carcinoma: Immunotherapy has greatly improved the survival and supplied an alternative to chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) with tumor programmed death ligand-1 (PD-L1) expression as low as 1% [1–3] or even irrespective of PD-L1 expression [4].